Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Standard Biotools (LAB) Gross Margin (2016 - 2026)

Standard Biotools has reported Gross Margin over the past 16 years, most recently at 47.83% for Q4 2025.

  • Quarterly Gross Margin rose 200.0% to 47.83% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 48.38% through Dec 2025, down 214.0% year-over-year, with the annual reading at 49.86% for FY2025, 54.0% up from the prior year.
  • Gross Margin was 47.83% for Q4 2025 at Standard Biotools, down from 48.51% in the prior quarter.
  • Over five years, Gross Margin peaked at 94.71% in Q3 2021 and troughed at 23.58% in Q2 2022.
  • The 5-year median for Gross Margin is 48.51% (2025), against an average of 55.73%.
  • The largest YoY upside for Gross Margin was 4860bps in 2021 against a maximum downside of -32579bps in 2021.
  • A 5-year view of Gross Margin shows it stood at 94.71% in 2021, then crashed by -56bps to 41.33% in 2022, then rose by 15bps to 47.39% in 2023, then decreased by -3bps to 45.84% in 2024, then grew by 4bps to 47.83% in 2025.
  • Per Business Quant, the three most recent readings for LAB's Gross Margin are 47.83% (Q4 2025), 48.51% (Q3 2025), and 48.84% (Q2 2025).